Brian L. Pearlman

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

Eric Lawitz, Mark Sulkowski, Reem Ghalib et al. · The Lancet · 2014 · 818 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

Eric Lawitz, Edward Gane, Brian L. Pearlman et al. · The Lancet · 2014 · 300 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1–infected slow responders

Brian L. Pearlman, Carole Ehleben, Sophia Saifee · Hepatology · 2007 · 268 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

Ira M. Jacobson, Eric Lawitz, Edward Gane et al. · Gastroenterology · 2017 · 239 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +12

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection

Mark Sulkowski, Hugo E. Vargas, Adrian M. Di Bisceglie et al. · Gastroenterology · 2015 · 179 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15